64724-29-4

Usage

Uses

Used in Pharmaceutical Research:
Z-(1)-ETHOXY-(2)-(TRIBUTYLSTANNYL)ETHYLEN is used as a research compound for its potential applications in the development of new pharmaceuticals. Its unique structure allows for the exploration of its interactions with biological targets and its potential therapeutic effects.
Used as a Reagent:
In the field of chemistry, Z-(1)-ETHOXY-(2)-(TRIBUTYLSTANNYL)ETHYLEN serves as a valuable reagent due to its specific chemical properties. It can be utilized in various chemical reactions and synthesis processes, contributing to the development of new compounds and materials.

InChI:InChI=1/C4H7O.3C4H9.Sn/c1-3-5-4-2;3*1-3-4-2;/h1,3H,4H2,2H3;3*1,3-4H2,2H3;/rC16H34OSn/c1-5-9-13-18(14-10-6-2,15-11-7-3)16-12-17-8-4/h12,16H,5-11,13-15H2,1-4H3/b16-12-

Upstream product

• 688-73-3 tri-n-butyl-tin hydride 
• 927-80-0 1-ethoxyacetylene 
• 23521-49-5 (Z)-1-bromo-2-ethoxyethene 
• 1461-22-9 tributyltin chloride 

Downstream Products

• 122223-71-6 3-<1-isopropyl-2-methyl-4-(4-fluorophenyl)-1H-pyrrol-3-yl>-(E)-propenal 
• 73958-00-6 (5S,6S)-epoxy-10-formyl-(7E,9E)-decadienoic acid methyl ester 
• 868551-58-0 ethyl 4-[(E)-2-ethoxyvinyl]-1-(4-fluorobenzyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxylate 
• 868660-48-4 ethyl 4-[2-ethoxyvinyl]-1-(4-fluorobenzyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxylate 
• 13294-31-0 (Z)-(2-ethoxyethenyl)benzene 
• 31172-40-4 (E)-3-ethoxy-1-phenylprop-2-ene-1-one 
• 143101-58-0 (E)-3-ethoxy-1-(4-methylphenyl)prop-2-en-1-one 
• 143101-59-1 (E)-3-ethoxy-1-(4-methoxylphenyl)prop-2-en-1-one 
• 143101-60-4 (E)-4-(3-ethoxy-1-oxoprop-2-en-1-yl)acetanilide 
• 128639-96-3 ethyl (Z)-4-(2-ethoxyethenyl)benzoate 
• 143101-61-5 ethyl (E)-4-(3-ethoxy-1-oxoprop-2-en-1-yl)benzoate 
• 1071206-15-9 (Z)-1-(2-ethoxyethenyl)-2-(methoxymethoxy)benzene 
• 128639-98-5 (Z)-4-(2-ethoxyethenyl)-N,N-dimethylaniline 
• 51417-51-7 7-bromo-1H-indole 

Relevant academic research and scientific papers

COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS

The present application provides novel optionally substituted fused pyridine and pyrimidine bicyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating FAK and/or Src activity by administering a therapeutically effective amount of one or more of the compounds to a subject. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the FAK and/or Src pathway. Advantageously, these compounds perform as dual FAK and/or Src inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

Pyrrolopyrimidine Compounds and Their Uses

The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases, particularly pyrrolopyrimidine compounds and derivatives are described which inhibit protein kinases. The organic compounds are useful in treating proliferative disease.

HETEROCYCLIC COMPOUNDS

The invention relates to compounds of formula I and salts thereof wherein the substituents are as defined in the specification, processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.

FUSED TRICYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1-R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, part

NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS

The invention relates to azacyclyl-substituted arylthienopyrimidinones and their derivatives of formula (I), and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one azacyclyl-substituted arylthienopyrimidinone of the invention or its derivative, and the use of the azacyclyl-substituted aryithienopyrimidinones of the invention and their derivatives as MCH antagonists.

Method of treating cancer using FPT inhibitors and antineoplastic agents

Disclosed is a method of treating cancer in a patient in need of such treatment comprising administering a therapeutically effective amount of an FPT inhibitor and therapeutically effective amounts of one or more antineoplastic agents. Methods of treating non small cell lung cancer, squamous cell cancer of the head and neck, CML, AML, non-Hodgkin's lymphoma and multiple myeloma are disclosed.

Novel farnesyl protein transferase inhibitors as antitumor agents

Disclosed are novel tricyclic compounds represented by the formula (1.0): and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Novel farnesyl protein transferase inhibitors as antitumor agents

Disclosed are novel tricyclic compounds represented by the formula (1.0): or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof

Compounds of the formula STR1 wherein R1 is C1-3 alkyl, and Z is STR2 wherein R7 is hydrogen, R8 or M, wherein R8 is a physiologically acceptable and hydrolyzable ester group, and M is a pharmaceutically acceptable cation, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.